SCHEMBL6023769

SCHEMBL6023769

C=CC1(CC(=O)OCC)CCOCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.40
LMNA P02545 2/20 0.40
POLB P06746 2/20 0.40
ALDH1A1 P00352 4/20 0.39
L3MBTL1 Q9Y468 2/20 0.37
RAB9A P51151 2/20 0.37
GAA P10253 3/20 0.36
MGAM O43451 1/20 0.35
SI P14410 1/20 0.35
MGAM2 Q2M2H8 1/20 0.35
RECQL P46063 1/20 0.35
KMT2A Q03164 2/20 0.35
NPSR1 Q6W5P4 2/20 0.33
MAPT P10636 2/20 0.33
TRPA1 O75762 1/20 0.33
HPGD P15428 1/20 0.33
CYP3A4 P08684 1/20 0.31
CYP2C19 P33261 1/20 0.31
CTDSP1 Q9GZU7 1/20 0.31
KDM4E B2RXH2 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8234342 0.88 GAA (0.41) TSHRLMNAALDH1A1L3MBTL1GAA
SCHEMBL31089194 0.85 TSHR (0.41) TSHRLMNAPOLBALDH1A1L3MBTL1
SCHEMBL9796453 0.83 KDM4E (0.40) TSHRALDH1A1L3MBTL1GAAMGAM
SCHEMBL13980758 0.83 GLA (0.35) TSHRLMNAALDH1A1RECQLCYP3A4
SCHEMBL8146725 0.81 TSHR (0.45) TSHRLMNAPOLBALDH1A1L3MBTL1
SCHEMBL24906928 0.78 ALDH1A1 (0.47) TSHRLMNAPOLBALDH1A1L3MBTL1
SCHEMBL19746316 0.77 GAA (0.38) TSHRLMNAALDH1A1L3MBTL1GAA
SCHEMBL2085077 0.76 TSHR (0.44) TSHRLMNAPOLBALDH1A1L3MBTL1
SCHEMBL16268204 0.76 TSHR (0.44) TSHRLMNAPOLBALDH1A1L3MBTL1
SCHEMBL4689889 0.75 CYP2C19 (0.32) TSHRLMNAALDH1A1CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024175907-A1 MACROCYCLIC ALPHA4BETA7 INTEGRIN INHIBITORS C4X DISCOVERY LIMITED (GB) 2024-08-29 WO disclosed
US-7125870-B2 Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme BRISTOL-MYERS SQUIBB COMPANY (US) 2006-10-24 US disclosed
US-20040122005-A1 Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme BRISTOL-MYERS SQUIBB COMPANY 2004-06-24 US disclosed
WO-2004043349-A2 ISOXAZOLINE DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES AND/OR TNF-ALPHA CONVERTING ENZYME BRISTOL-MYERS SQUIBB COMPANY (US) 2004-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040122005-A1 Isoxazoline derivatives as inhibitors of matrix metalloproteinases and/or TNF-alpha converting enzyme MMP2, MMP1, MMP9 TSHR 1507/4885LMNA 391/4885POLB 1177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.